Transcript ONE FAMILY’S STORY” - FLC Mid

“ONE FAMILY’S STORY”
John Emond, NASA Headquarters
Human Interest Panel
FLC Mid-Atlantic Region Annual Conference
September 16, 2009
GRIM STATISTICS
2009 ESTIMATED U.S. CANCER CASES AND DEATHS
Source: American Cancer Society
MEN
TOTAL CASES:
766,130
WOMEN
TOTAL CASES:
713,220
TOTAL DEATHS: 292,540
TOTAL DEATHS: 269,800
CASE BY TYPE:
• Prostate 25%
• Lung and Bronchus 15%
• Colon and Rectum 10%
• Urinary Bladder 7%
• Skin Melanoma 5%
• Non-Hodgkin's Lymphoma 5%
CASE BY TYPE:
• Breast 27%
• Lung and Bronchus 14%
• Colon and Rectum 10%
• Uterine 6%
• Non-Hodgkin's Lymphoma 4%
• Skin Melanoma 4%
DEATH BY TYPE:
• Lung and Bronchus 30%
• Prostate 9%
• Colon and Rectum 9%
• Pancreas 6%
• Leukemia 4%
DEATH BY TYPE:
• Lung and Bronchus 26%
• Breast 15%
• Colon and Rectum 9%
• Pancreas 6%
• Ovary 5%
2
LIFETIME PROBABILITY
DEVELOPING CANCER, 2003-2005 DATA
Source: NIH/NCI
MEN
ALL TYPES OF CANCER: 1 IN 2
PROSTATE: 1 IN 6
WOMEN
ALL TYPES OF CANCER: 1 IN 3
BREAST: 1 IN 8
3
John and Mary Brough Emond
Brough/Emond Family Does Not Need Statistics
John and Dolores Brough, Parents
9 sons and daughters
Joseph and Ellen Emond, Parents
3 sons
John Brough died brain cancer age 53
Son Joseph:
• Treated for prostate cancer
Daughter Dolores:
• Treated for breast cancer
Husband William:
• Treated for Non-Hodgkin's Lymphoma
Son James:
• Treated for prostate cancer
Son John:
• Treated for Non-Hodgkin's Lymphoma
Son John:
• Diagnosed with prostate cancer, May 2009
Son Vincent:
• Treated for bladder cancer
Daughter Maureen:
• Treated for basal skin cancer
4
Early Detection
• Annual checkup March 2009 yielded substantial spike in
Prostate-Specific Antigen (PSA) level in blood
2006
2007
2008
2009
1.1
1.3
1.7
6.7
• Subsequent blood tests confirmed elevated PSA level,
additional testing required
• Joined an NIH clinical study April, 2009 for prostate analysis
5
NIH/PHILIPS MEDICAL SYSTEMS
COLLABORATION
• NIH study merges MR imaging and biopsy to more accurately detect
possible presence of prostate cancer. I was 95th participant in study
• Collaboration between NIH and Philips Medical Systems
(CRADA 01864) with NIH Drs. Peter Pinto, Peter Choyke and colleagues
• Philips provides NIH access to software code, latest imaging technology,
and 2 onsite physicists to develop quantitative MRI
• NIH provides Philips with real-time feedback: what does, does not work
• Jointly develop innovative technologies including fusion MRI and
ultrasound fusion biopsy
6
Diagnosis
• NIH MRI scan April 16, endorectal and phased array
surface coil
– Two suspicious sites identified in the prostate
• “Small subtle age lesion in the midgland…making this a moderate
risk lesion”
– Family history of brothers with prostate cancer increases
this as risk
• NIH Biopsy May 19
– Biopsy of 18 sites included usual random sampling of
prostate but also targeted within the 18 the two suspicious
sites found by the MRI
– Biopsy revealed 5 sites positive for prostate cancer
including the 2 sites identified in the MRI
– Prostate cancer “Gleason Score” 6 (3+3), easier to treat
compared to higher Gleason scores
7
Treatment
• Prostate surgery July 27, Johns Hopkins, Baltimore
– Released from hospital July 29 (food was pretty good)
• Successful Operation:
– Post-surgery pathology report cited “negative margins”,
indicating cancer fully contained in prostate
– First post-surgery PSA reading was < 0.1 nanograms per
milliliter of blood; threshold of 0.2ng or less is success
• Indicators point to cancer cure
8
CONCLUSIONS
• Cancer touches many lives
– Some families have more than their share
– Cancer creates sadness and trauma far beyond what is seen in dry
statistics/actuarial tables; there are real people behind these numbers!!
• Cancer remains a deadly threat but technology advances across a
broad front towards early detection, treatment, and hopefully cure.
• NIH CRADA with Philips Medical Systems
– Fuses data from MRI/Magnetic Resonance Imaging and prostate biopsy
– Provides a targeted approach to biopsy site selection rather than purely
random sample approach
• Purely random biopsy site selection can lead to false negative findings, false sense
of security when in fact cancer can be present
• My early cancer detection including the NIH MRI study, and
subsequent treatment, is giving me the best chance for cancer cure.
9
IF ANYONE WOULD LIKE TO
DISCUSS DEALING WITH PROSTATE
CANCER I WOULD BE HAPPY TO
TALK TO YOU:
JOHN EMOND,
INNOVATIVE PARTNERSHIPSPROGRAM,
NASA HEADQUARTERS
PHONE: 202-358-1686
E-MAIL: [email protected]
10